Table 1.
Participating cohorts by baseline eGFR
| End-stage renal disease | All-cause mortality | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Participants N |
Serum creatinine, Median (IQR) |
Events (n) |
Follow- up Mean (SD), years |
Events (n) |
Follow- up Mean (SD), years |
||||
|
| |||||||||
| Baseline eGFR | Baseline eGFR | Baseline eGFR | Baseline eGFR | Baseline eGFR | Baseline eGFR | ||||
|
<60 ml/min/1.73m2 |
60+ ml/min/1.73m2 |
<60 ml/min/1.73m2 |
60+ ml/min/1.73m2 |
<60 ml/min/1.73m2 |
60+ ml/min/1.73m2 |
||||
|
| |||||||||
| Meta-Analysis | |||||||||
|
| |||||||||
| Baseline, 1-y |
466,068
(458,965) * |
1,291,818
(1,071,683) * |
2(2-3) | 11,214 | 1,130 |
3.1
(2.3) |
144,558 | 79,386 |
4.4
(3.6) |
|
| |||||||||
| Baseline, 2-y |
363,143
(356,813) * |
1,226,114
(984,380) * |
3(3-5) | 7,523 | 1,009 |
2.4
(2.2) |
97,795 | 60,808 |
3.7
(3.6) |
|
| |||||||||
| Baseline, 3-y |
235,560
(230,178) * |
1,023,917
(850,096) * |
5 (4-5) | 4,058 | 1,101 |
2.0
(2.9) |
55,135 | 47,356 |
3.2
(4.0) |
|
| |||||||||
| Participating cohorts’ data for the 2 year baseline period | |||||||||
|
| |||||||||
| AASK | 744 | 169 | 7 (6-7) | 243 | 8 | 6 (3) | 112 | 24 | 6 (3) |
| ADVANCE | 1,542 | 8,457 | 4 (4-4) | 16 | 21 | 3 (0.5) | 150 | 407 | 3 (0.5) |
| Aichi | 14 | 1,798 | 2(2-3) | 1 | 15 | 7 (2) | |||
| AKDN | 35,617 | 257,597 | 3 (3-4) | 206 | 63 | 2 (1) | 3,878 | 5,779 | 2 (1) |
| ARIC | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| BC CKD | 7,986 | 656 | 10 (8-14) | 1,178 | 53 | 2 (1) | 1,730 | 67 | 3 (1) |
| CARE | 580 | 3,101 | 3 (3-3) | 62 | 150 | 3 (1) | |||
| CCF | 17,102 | 31 | 6 (4-9) | 290 | 1 | 1 (1) | 1,746 | 3 | 1 (1) |
| CHS | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| CIRCS | 175 | 4,286 | 3 (2-3) | 53 | 564 | 17 (4) | |||
| CRIB | 189 | 1 | 2 (2-2) | 63 | 0 | 4 (2) | 45 | 0 | 5 (2) |
| Framingham | 46 | 652 | 2 (2-2) | 17 | 54 | 6 (1) | |||
| Geisinger | 14,850 | 20 | 6 (4-9) | 257 | 0 | 3 (2) | 2,287 | 4 | 3 (2) |
| GLOMMS 1 | 645 | 2 | 11 (7-20) | 58 | 0 | 3 (1) | 274 | 1 | 3 (1) |
| IPHS | 2,147 | 60,319 | 3 (3-3) | 983 | 10,019 | 12 (3) | |||
| KP Hawaii | 5,468 | 15,140 | 5 (4-8) | 134 | 19 | 1 (0.7) | 364 | 329 | 1 (1) |
| KPNW | 320 | 202 | 7(4-12) | 21 | 10 | 4 (2) | 167 | 73 | 5 (2) |
| KSHS | 217 | 62,810 | 3 (3-5) | 5 | 169 | 3 (1) | |||
| Maccabi | 27,616 | 577,024 | 8(7-9) | 724 | 177 | 3 (1) | 6,199 | 14,042 | 4 (1) |
| MASTERPLAN | 513 | 66 | 8(7-9) | 111 | 3 | 4 (1) | 79 | 4 | 4 (1) |
| MDRD | 591 | 27 | 8 (7-8) | 431 | 13 | 7 (5) | 270 | 5 | 13 (4) |
| MESA | n/a | n/a | n/a | n/a | n/a | n/a | |||
| MRFIT | 185 | 11,342 | 3 (3-3) | 30 | 239 | 21 (6) | 86 | 3,900 | 23 (8) |
| NephroTest | 465 | 88 | 3 (2-3) | 92 | 3 | 3 (2) | 61 | 1 | 4 (2) |
| NZDCS | 1,913 | 7,093 | 3 (3-5) | 152 | 100 | 6 (2) | 728 | 1,081 | 6 (2) |
| Ohasama | 38 | 1,039 | 3 (3-3) | 6 | 59 | 7 (1) | |||
| Pima | 12 | 1,594 | 2 (2-2) | 6 | 101 | 12 (8) | 10 | 343 | 13 (8) |
| PREVEND | 406 | 4,334 | 2 (2-2) | 34 | 98 | 4 (1) | |||
| Rancho Bernardo | 33 | 174 | 2 (2-2) | 9 | 17 | 7 (1) | |||
| RENAAL | 1,083 | 118 | 10 (9-10) | 195 | 5 | 1 (1) | 147 | 7 | 1 (1) |
| Severance | 140 | 6,105 | 2 (2, 3) | 6 | 119 | 12 (2) | |||
| Sunnybrook | 1,484 | 1,173 | 7 (5-11) | 168 | 18 | 3 (2) | 437 | 90 | 5 (3) |
| Taiwan MJ | 2,247 | 96,533 | 2(2-3) | 362 | 1,676 | 7 (4) | |||
| VA CKD | 238,488 | 103,580 | 5 (4-7) | 3,148 | 175 | 3 (1) | 77,337 | 21,552 | 3 (1) |
| ZODIAC | 287 | 583 | 3 (3-3) | 150 | 156 | 7 (3) | |||
n/a: Not available for 2y baseline period but those studies are included in other baseline periods. eGFR: estimated glomerular filtration rate. IQR: interquartile range. SD: standard deviation.
Blank cells indicate the cohort did not have data on end-stage renal disease. Total numbers for cohorts with both end-stage renal disease and all-cause mortality as outcomes use data from the end-stage renal disease analysis.
*
Total number for end-stage renal disease analyses.